Is the price fair?
What GSK's price assumes
GSK plc did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 1.58× revenue.
1.58
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 11.9
Price / book · as of 2025-FY
- EV / sales
- 1.67
EV / sales
Details›
- Price / book2025-FY
- 11.9
- EV / EBIT2025-FY
- 8.21
- EV / sales2025-FY
- 1.67
- Market capitalisation
- $101.5B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #8 of 16 by Smart Score